Printer Friendly

ONCOR AND THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE IN AGREEMENT TO RESEARCH AND COMMERCIALIZE NEW CANCER GENES

 ONCOR AND THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
 IN AGREEMENT TO RESEARCH AND COMMERCIALIZE NEW CANCER GENES
 GAITHERSBURG, Md., Oct. 21 /PRNewswire/ -- Oncor, Inc. (NASDAQ: ONCR) and the Johns Hopkins University School of Medicine announced today a joint collaborative research agreement for the discovery and commercialization of new generic technologies for the detection of cancer.
 Oncor will fund research projects in the laboratory of David Sidransky, M.D. in the Department of Otolaryngology -- Head and Neck Surgery of the Johns Hopkins University School of Medicine and the Johns Hopkins Hospital. Prior to starting his own laboratory, Dr. Sidransky was a post-doctoral fellow in the laboratory of Bert Vogelstein, M.D. at Johns Hopkins.
 Under the terms of this three-year agreement, Oncor holds a first option to an exclusive, worldwide royalty-bearing license for new technology (both diagnostic and therapeutic) discovered in Dr. Sidransky's laboratory in the course of performing the agreed-upon research projects in lung, bladder, head and neck cancer.
 Commenting on the agreement, Oncor's Chairman and CEO Stephen Turner said, "This is a landmark academic/industrial effort from several standpoints. First, it provides Oncor access to very basic, proprietary potential discoveries in cancer genetics. Second, it combines two centers of excellence in cancer genetics -- Johns Hopkins' premier position in the discovery of new cancer genes and Oncor's leading position in the commercialization of DNA probe-based cancer detection and management. This close working relationship should allow us to conduct clinical studies on promising new genetic discoveries and rapidly commercialize these significant developments in cancer genetics, accelerating their use in mainstream clinical medicine."
 "I am excited by the prospect of having Oncor as a partner in my research efforts," said Dr. Sidransky. "Their in-house expertise, including genomic libraries and DNA probe chemistries, will be a helpful adjunct to our own laboratory. These probes will allow us to identify new genetic changes that may be useful as specific markers for cancer."
 Dr. Vogelstein, Professor of Oncology at The Johns Hopkins University School of Medicine, stated, "Dr. Sidransky is one of the most talented physician scientists who I've been associated with. The new initiatives he is undertaking in the cancer diagnostics field are extremely promising."
 "Dr. Sidransky has brought an important new dimension to our Department of Otolaryngology -- Head and Neck Surgery, which has been the source of so many important contributions to medical science," commented Michael Johns, Dean of the School of Medicine. "The agreement with Oncor is also important from the standpoint of economic development in Maryland because it ensures that certain new technology from Dr. Sidransky's laboratory will be licensed to a Maryland company."
 Oncor develops, manufactures and markets DNA probe test systems and related products for use in the diagnosis, monitoring and management of cancer and other genetic diseases.
 -0- 10/12/92
 /CONTACT: Stephen Turner or George R. Evanega, Ph.D., of Oncor, Inc., 301-963-3500, or (fax) 301-926-6129; or Joann Rodgers or Carol Pearson of The Johns Hopkins University, 410-955-6680, or (fax) 410-955-4452/
 (ONCR) CO: Oncor, Inc.; Johns Hopkins University School of Medicine ST: Maryland IN: MTC SU:


TS-EE -- NY003 -- 2671 10/21/92 08:30 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 21, 1992
Words:519
Previous Article:TELEMATICS INTERNATIONAL DOUBLES PROFITS YEAR-TO-DATE 1992
Next Article:POLYGRAM FILMED ENTERTAINMENT ENTERS THREE-YEAR PACT WITH FOSTER
Topics:


Related Articles
ONCOR SIGNS EXCLUSIVE LICENSING AGREEMENT FOR COMMERCIALIZATION OF p58 GENE, POTENTIAL SUPPRESSOR OF MALIGNANT MELANOMA AND OTHER TUMORS
TARGETED GENETICS SIGNS RESEARCH AGREEMENT WITH JOHNS HOPKINS UNIVERSITY
ONCOR ANNOUNCES FORMATION OF A GENETIC PROFILING SUBSIDIARY ACQUIRES EXCLUSIVE RIGHTS TO HEREDITARY CANCER INSTITUTE
HUMAN GENOME SCIENCES TO COLLABORATE WITH JOHNS HOPKINS MEDICAL SCHOOL ON COLON CANCER RESEARCH
Genzyme Molecular Oncology Receives $5 Million Milestone Payment Related To European Patent Rights to p53 Tumor Suppressor Gene.
Affymetrix and AMDeC Sign AcademicAccess Preferred Agreement.
Affymetrix to provide technology to New York research institutions.
Millennium Appoints Edward Miller, CEO and Dean of Johns Hopkins Medicine, To Board of Directors.
Genzyme Genetics licenses colon cancer diagnostic.
Threshold Pharmaceuticals Announces Appointment of Scientific Advisory Board Members; Board Will Help Guide Company's Oncology Research and Clinical...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters